lower
respiratori
tract
infect
account
estim
million
death
make
third
common
caus
death
worldwid
commun
acquir
pneumonia
cap
caus
nearli
death
england
wale
cost
europ
around
million
annual
estim
per
adult
hospitalis
pneumonia
year
hospit
acquir
pneumonia
hap
defin
occur
h
admiss
healthcar
facil
caus
differ
spectrum
antibiot
resist
bacteri
pathogen
occur
commun
ventil
associ
pneumonia
vap
defin
occur
h
intub
invas
artifici
ventil
two
entiti
combin
hap
vap
common
nosocomi
infect
develop
world
hap
complic
around
hospit
admiss
incid
vap
intub
patient
around
associ
mortal
around
retrospect
match
cohort
studi
kollef
et
al
found
patient
develop
vap
intub
longer
spent
longer
icu
hospit
greater
period
time
estim
addit
cost
vap
per
patient
larg
amount
empir
broad
spectrum
antibiot
use
treat
pneumonia
inadvert
promot
antimicrobi
resist
amr
problem
identifi
one
lead
threat
global
health
today
oneil
report
commiss
uk
govern
highlight
need
develop
nation
take
lead
tackl
amr
part
specif
recommend
antibiot
prescript
support
diagnost
test
avail
uk
govern
recent
publish
fiveyear
action
plan
tackl
amr
emphasis
need
improv
diagnost
support
antibiot
prescrib
includ
target
abl
report
percentag
antimicrobi
prescript
support
diagnost
test
decis
make
tool
time
administr
appropri
antibiot
central
tenant
care
patient
pneumonia
yet
goldstandard
microbiolog
diagnosi
remain
tradit
slow
cultur
base
method
take
greater
h
identifi
organ
often
greater
h
provid
phenotyp
antibiot
sensit
data
cultur
insensit
detect
pathogen
patient
clinic
diagnos
pneumonia
even
smaller
proport
administr
antibiot
recent
year
sever
rapid
syndrom
molecular
test
pneumonia
develop
offer
potenti
revolutionis
treatment
provid
inform
clinician
realtim
pathogen
present
like
antibiot
sensit
also
detect
genotyp
marker
resist
multipl
studi
demonstr
superior
diagnost
accuraci
pcr
base
platform
detect
bacteri
pathogen
sputum
compar
standard
cultur
review
discuss
commerci
avail
syndrom
molecular
panel
pneumonia
potenti
clinic
impact
challeng
implement
front
line
diagnost
test
greatest
potenti
clinic
benefit
rapid
syndrom
test
pneumonia
abl
better
utilis
antibiot
superior
diagnost
yield
multiplex
pcr
mean
pathogen
detect
rapidli
much
greater
proport
patient
therapi
quickli
tailor
respons
organ
situat
allow
narrow
antimicrobi
therapi
exampl
identif
streptococcu
pneumonia
facilit
chang
antibiot
penicillin
geograph
area
low
preval
penicillin
resist
pneumonia
case
may
facilit
chang
escal
antimicrobi
therapi
exampl
identif
methicillin
resist
staphylococcu
aureu
mrsa
would
cover
empir
regimen
mani
area
absenc
detect
also
help
sensit
compar
cultur
molecular
assay
high
reassur
clinician
organ
present
support
decis
stop
unnecessari
antibiot
deescal
antibiot
use
empir
cover
organ
subsequ
detect
impact
improv
use
antibiot
twofold
firstli
earlier
appropri
antibiot
improv
clinic
outcom
includ
mortal
length
stay
secondli
prevent
unnecessari
broadspectrum
antibiot
use
facilit
antibiot
stewardship
reduc
antibiot
relat
advers
event
aetiolog
cap
hapvap
highli
variabl
differ
region
time
reflect
studi
caus
microbi
agent
identifi
cultur
patient
underli
lung
diseas
exampl
chronic
obstruct
pulmonari
diseas
colonis
microbi
flora
typic
pathogen
hap
result
may
develop
commun
acquir
infect
caus
agent
pneumonia
haemophiliu
influenza
aureu
moraxella
catarrhali
atyp
organ
includ
mycoplasma
pneumonia
legionella
pneumophila
cultur
sputum
patient
cap
mani
organ
predict
resist
pattern
interpret
local
epidemiolog
data
gadsbi
et
al
develop
intern
valid
syndrom
molecular
assay
pneumonia
use
test
sputum
sampl
adult
admit
hospit
cap
assay
detect
pathogen
patient
oppos
patient
use
routin
cultur
result
propos
antibiot
prescript
cap
could
deescal
base
result
multiplex
pcr
test
major
potenti
intervent
involv
stop
clarithromycin
atyp
organ
detect
narrow
antibiot
like
sensit
pathogen
detect
hap
vap
frequent
cultur
bacteri
pathogen
includ
aureu
pseudomona
aeruginosa
klebsiella
speci
escherichia
coli
acinetobact
speci
enterobact
speci
empir
regimen
therefor
broad
spectrum
larg
number
antibiot
consum
absenc
certain
organ
exampl
p
aeruginosa
could
facilit
narrow
antimicrobi
spectrum
knockon
effect
reduc
antibiot
relat
advers
effect
improv
stewardship
furthermor
common
gram
neg
isol
increasingli
resist
pneumonia
surveil
studi
rapid
molecular
detect
resist
gene
facilit
earlier
initi
effect
antibiot
lead
better
outcom
adult
respiratori
virus
found
approxim
one
third
commun
acquir
pneumonia
case
one
studi
found
patient
admit
intens
care
pneumonia
posit
respiratori
viru
broad
rang
virus
detect
detect
certain
virus
influenza
adenoviru
known
caus
pneumonia
coupl
absenc
detect
bacteria
low
level
serum
biomark
procalcitonin
elev
patient
bacteri
infect
could
support
decis
stop
use
abbrevi
cours
antibiot
respoc
trial
pragmat
randomis
control
trial
test
patient
commun
acquir
acut
respiratori
ill
use
biofir
respiratori
panel
test
comprehens
respiratori
virus
atyp
bacteria
pointofcar
found
patient
test
filmarray
significantli
like
receiv
singl
dose
shorter
cours
antibiot
also
found
signific
reduct
length
hospit
stay
intervent
group
along
improv
use
neuraminidas
inhibitor
nai
patient
influenza
current
licenc
antivir
agent
respiratori
virus
influenza
benefit
nai
treatment
greatest
start
within
h
symptom
onset
evid
adult
suggest
ongo
benefit
start
beyond
time
recent
studi
suggest
treatment
earlier
admiss
hospit
improv
outcom
irrespect
overal
durat
ill
time
identif
treatment
critic
antivir
treatment
respiratori
virus
includ
respiratori
syncyti
viru
rsv
develop
sinc
infect
control
method
includ
patient
sourc
isol
deep
clean
target
decolonis
highli
success
reduc
spread
mrsa
enhanc
infect
control
practic
recommend
number
pathogen
may
present
patient
pneumonia
earli
identif
reduc
spread
organ
especi
hospitalis
patient
exampl
found
commerci
avail
molecular
test
extend
spectrum
beta
lactamas
esbl
carbapenemas
produc
enterobacteriacea
cpe
mrsa
influenza
rsv
uk
mandatori
requir
report
certain
infecti
diseas
public
health
england
investig
l
pneumophilia
associ
outbreak
devic
aerosol
water
case
uk
earlier
sensit
detect
would
allow
outbreak
investig
occur
sooner
potenti
stop
case
occur
current
time
fda
approv
ce
mark
syndrom
molecular
panel
pneumonia
commerci
avail
filmarray
biofir
diagnost
llc
salt
lake
citi
utah
us
pneumonia
panel
unyvero
cureti
gmbh
holzgerlingen
germani
hospitalis
pneumonia
hpn
panel
fast
track
diagnost
respiratori
panel
fast
track
diagnost
sarl
luxembourg
anoth
avail
platform
larg
number
target
insuffici
bacteri
target
consid
true
pneumonia
panel
consid
brief
commerci
avail
platform
summaris
tabl
author
awar
panel
develop
mobidiag
bruker
acceler
axo
scienc
publish
data
avail
latter
also
sever
research
group
develop
syndrom
molecular
pneumonia
test
notabl
gadsbi
et
al
multitud
respiratori
pathogen
multiplex
panel
target
respiratori
virus
atyp
bacteri
target
small
rang
typic
bacteria
beyond
scope
review
articl
includ
assay
target
wide
rang
typic
pathogen
pneumonia
fda
approv
ce
mark
platform
use
nest
realtim
pcr
detect
clinic
import
respiratori
target
semiquantit
bacteri
target
qualit
atyp
bacteri
target
furthermor
pneumonia
panel
detect
pathogen
much
higher
proport
sampl
cultur
buchan
et
al
report
filmarray
detect
bacteri
target
specimen
routin
cultur
equat
increas
total
bacteri
detect
rel
abund
organ
bacteri
target
estim
base
realtim
pcr
rel
materi
known
quantiti
group
report
bin
repres
approxim
genom
copi
bacteri
nucleic
acid
per
millilitr
specimen
respect
concord
refer
molecular
test
high
expect
overal
concord
bin
refer
sputum
cultur
cfuml
concentr
lower
around
highli
variabl
organ
manufactur
advis
clinic
correl
interpret
semiquantit
result
date
publish
prospect
intervent
studi
evalu
clinic
impact
use
pneumonia
panel
patient
pneumonia
observ
data
base
lower
respiratori
tract
assay
preced
final
fda
approv
pneumonia
panel
suggest
chang
antibiot
could
support
case
hpn
panel
ce
mark
run
unyvero
platform
includ
unyvero
lysat
unyvero
cockpit
unyvero
analyz
amplicon
gener
parallel
multiplex
pcr
reaction
qualit
detect
hybridis
array
singl
use
cartridg
wide
rang
bacteri
resist
gene
target
includ
assay
valid
use
sputum
includ
expector
sputum
bal
et
aspir
like
filmarray
unyvero
platform
design
sampletoansw
solut
take
min
low
skill
handson
time
total
turnaround
time
h
equival
test
lower
respiratori
tract
panel
lrt
fda
approv
us
valid
use
tracheal
aspir
manufactur
report
diagnost
sensit
bacteri
detect
compar
refer
cultur
molecular
detect
case
discrep
major
target
diagnost
perform
data
present
manufactur
resist
marker
detect
align
poorli
organ
antibiogram
exampl
match
meca
detect
quinolon
resist
marker
e
coli
issu
note
gadbsi
et
al
assay
sensit
antibiot
resist
detect
two
predecessor
hpn
cartridg
develop
ce
mark
earlier
later
former
evalu
extens
personn
et
al
found
test
sensit
bacteri
detect
run
failur
rate
extens
discrep
regard
sensit
test
furthermor
test
unabl
differenti
pneumonia
miti
group
papan
et
al
report
low
sensit
gram
posit
organ
evalu
paediatr
sampl
resist
panel
broad
lack
sever
key
emerg
carbapenemas
gene
target
panel
rebalanc
remov
less
clinic
relev
resist
gene
ad
target
pneumonia
pneumonia
sensit
bacteri
detect
remain
high
assess
ozongwu
et
al
albeit
high
overal
run
failur
rate
target
panel
hpn
manufactur
claim
higher
sensit
specif
date
publish
randomis
control
trial
evalu
clinic
impact
unyvero
hpn
system
patient
pneumonia
jamal
et
al
perform
nonrandomis
intervent
studi
use
assay
antibiot
adjust
base
result
pathogen
detect
compar
cultur
turnaround
time
result
quick
h
compar
cultur
h
larg
proport
patient
antibiot
chang
base
result
howev
small
number
patient
studi
lack
compar
group
make
definit
conclus
imposs
gadsbi
et
al
retrospect
test
bal
sampl
review
patient
note
report
patient
posit
standard
care
microbiolog
could
potenti
chang
antibiot
earlier
base
result
convers
report
fals
neg
result
posit
cultur
could
caus
harm
act
upon
respiratori
pathogen
panel
differ
first
two
test
discuss
exclus
laboratori
centr
assay
ce
mark
respiratori
pathogen
kit
use
sever
standard
laboratori
cycler
report
standard
turnaround
time
although
greater
h
posit
signal
detect
eight
multiplex
realtim
pcr
reaction
autom
process
consider
longer
handson
time
requir
skill
extract
setup
littl
publish
data
compar
differ
syndrom
molecular
pneumonia
test
enn
et
al
inhal
group
present
data
eccmid
compar
unyvero
filmarray
surplu
intens
care
respiratori
tract
sampl
filmarray
slightli
greater
sensit
common
pathogen
fewer
major
discord
defin
routin
cultur
find
undetect
organ
fewer
machin
failur
unyvero
slightli
higher
specif
overal
concord
refer
cultur
whilst
data
present
syndrom
molecular
test
pneumonia
clearli
demonstr
high
accuraci
detect
mani
pathogen
cultur
data
yet
publish
show
translat
improv
antibiot
use
clinic
benefit
molecular
diagnost
studi
blood
stream
infect
shown
improv
diagnost
perform
neglig
impact
clinic
outcom
result
provid
clinician
along
infect
specialist
advic
seem
like
wealth
inform
gener
requir
care
interpret
infect
specialist
consult
clinician
directli
care
patient
benefit
maximis
rapid
syndrom
molecular
platform
potenti
significantli
improv
use
antibiot
clinic
outcom
patient
pneumonia
high
qualiti
randomis
control
trial
urgent
requir
evalu
clinic
impact
awar
trial
current
underway
set
may
address
evid
gap
saripoc
studi
singl
centr
randomis
control
trial
rct
recruit
critic
unwel
patient
pneumonia
southampton
uk
inhal
studi
uk
multicentr
rct
recruit
critic
unwel
patient
hap
vap
pibcap
uk
multicentr
rct
recruit
patient
cap
norcap
trial
norway
singl
centr
rct
set
also
aim
recruit
patient
cap
singl
centr
rct
edinburgh
use
molecular
test
broader
commun
acquir
lrti
microbi
diagnosi
first
two
studi
test
patient
pointofcar
wherea
other
use
rapid
laboratorybas
test
antibiot
deescal
base
result
key
compon
antibiot
stewardship
wide
accept
good
practic
trial
look
efficaci
safeti
antimicrobi
deisol
base
cultur
result
spars
vast
major
publish
studi
observ
comparison
studi
mani
variabl
hap
cap
vap
icu
nonicu
sever
sepsi
etc
fraught
difficulti
furthermor
due
geograph
variabl
caus
organ
prescrib
practic
often
poorli
transferr
region
knowledg
intervent
studi
look
safeti
efficaci
antimicrobi
deescal
base
multiplex
pcr
pathogen
pneumonia
studi
date
made
deescal
intervent
least
h
patient
stabilis
cultur
result
avail
idsa
nation
institut
clinic
excel
nice
cite
urgent
need
wellrun
rct
impact
deescal
antimicrobi
therapi
idsa
american
thorac
societi
advis
antibiot
deescal
hapvap
accord
cultur
result
basi
expert
opinion
cite
high
level
confid
reduc
cost
burden
side
effect
like
deescal
also
reduc
antimicrobi
resist
small
number
intervent
studi
look
antibiot
deescal
base
upon
microbiolog
cultur
result
hapvap
suggest
practic
safe
high
qualiti
data
outcom
includ
length
intens
care
stay
antibiot
save
lack
conflict
metaanalysi
khan
et
al
observ
studi
review
antibiot
deescal
pneumonia
icu
hap
vap
found
differ
mortal
deescal
accord
cultur
result
nt
context
cap
idsa
nicebt
guidelin
recommend
organ
direct
therapi
pathogen
identifi
cultur
high
qualiti
data
lack
observ
data
limit
intervent
data
suggest
safe
systemat
review
paul
et
al
includ
studi
cap
hap
vap
blood
stream
infect
review
found
associ
deescal
surviv
pneumonia
ci
concern
rais
high
sensit
molecular
test
lead
excess
detect
colonis
flora
may
paradox
increas
unnecessari
antibiot
use
particularli
pertin
expector
sputa
small
number
potenti
pathogen
bacteria
present
absenc
diseas
potenti
solut
develop
semiquantit
molecular
method
biofir
r
filmarray
r
pneumonia
panel
provid
represent
amount
bacteri
dna
present
highli
concord
refer
molecular
techniqu
highlight
studi
use
unyvero
molecular
detect
resist
gene
may
correl
poorli
phenotyp
sensit
current
form
detect
gene
panel
organ
exampl
mec
gene
colonis
coagulas
neg
staphylococci
may
incorrectli
attribut
organ
panel
clinician
need
cautiou
interpret
result
well
rel
quicker
run
time
syndrom
multiplex
molecular
test
could
potenti
deploy
pointofcar
resppoc
trial
brendish
et
al
demonstr
respiratori
viral
panel
logist
feasibl
associ
number
clinic
benefit
compar
routin
clinic
care
post
hoc
analysi
patient
test
posit
respiratori
virus
trial
highlight
associ
rapid
turnaround
time
defin
h
shorter
hospit
admiss
shorter
durat
antibiot
therapi
belief
pointofcar
test
repres
ideal
strategi
new
rapid
diagnost
test
platform
allow
clinician
maximis
benefit
accur
test
earli
decisionmak
process
clearli
rigor
qualiti
assur
essenti
diagnost
test
irrespect
site
test
also
note
test
describ
articl
current
clia
waivereda
requir
use
pointofcar
us
rapid
syndrom
molecular
test
pneumonia
improv
diagnost
accuraci
compar
current
gold
standard
cultur
provid
result
real
time
era
widespread
amr
use
potenti
dramat
improv
ration
use
antibiot
improv
clinic
outcom
patient
pneumonia
high
qualiti
data
well
conduct
randomis
control
trial
urgent
need
assess
impact
platform
antibiot
use
patient
outcom
pool
declar
interest
none
clark
tw
receiv
speaker
fee
reimburs
travel
honoraria
biofir
llc
biomerieux
also
receiv
equip
consum
compani
purpos
independ
research
commerci
entiti
input
manuscript
research
receiv
specif
grant
fund
agenc
public
commerci
notforprofit
sector
